Welcome to our dedicated page for Fresenius Medical Care news (Ticker: $FMS), a resource for investors and traders seeking the latest updates and insights on Fresenius Medical Care stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fresenius Medical Care's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fresenius Medical Care's position in the market.
Rhea-AI Summary
Fresenius Medical Care (FME) delivers on commitments during a year of fundamental transformation, making progress towards sustainability goals in key areas such as patient satisfaction, diversity in management, and climate target roadmap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
-
Rhea-AI Summary
Fresenius Medical Care introduces Augmented Reality (AR) training application for ICU staff to enhance learning experience and address nursing shortages.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
-
Rhea-AI Summary
Fresenius Medical Care appoints Jörg Häring as Global Head of Legal, Compliance, and Human Resources, effective June 1, 2024. Häring brings extensive expertise in corporate governance and legal matters from his previous roles in the energy and healthcare sectors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
Rhea-AI Summary
Fresenius Medical Care sells dialysis clinic networks in Latin America to DaVita Inc. for USD 300 million, impacting revenue and profitability negatively in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.19%
Tags
-
Rhea-AI Summary
Fresenius Medical Care reports revenue growth of 5% in 2023 driven by favorable business development and operating income growth of 15%, exceeding expectations. The company successfully executed a turnaround plan resulting in labor productivity improvements and positive pricing. Key divestments were announced, leading to strong cash flow performance and reduced financial leverage. A dividend of €1.19 per share is proposed, with continued revenue and accelerated operating income growth projected for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
-
Rhea-AI Summary
Fresenius Medical Care (FME) has received FDA 510(k) clearance for its 5008X Hemodialysis System, allowing the company to offer high-volume hemodiafiltration therapy in the U.S. The system is expected to be launched in 2025, aiming to bring a new standard of care in dialysis therapy to the U.S. market. The groundbreaking CONVINCE study showed a 23% decrease in mortality rates for patients treated with high-volume hemodiafiltration compared to high-flux hemodialysis. The company's global innovation leadership in medical device and membrane engineering technologies is highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
Rhea-AI Summary
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives to its Supervisory Board. This move comes after the company's change of legal form into a German stock corporation and aims to provide full and equal representation on the board. The Board now comprises six women and six men, exceeding the statutory minimum gender quota for the Supervisory Board of 30 percent each. The appointed members bring a broad range of experience and knowledge to the Board, aiming to further develop Fresenius Medical Care successfully for the benefit of patients, employees, and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
-
Rhea-AI Summary
Fresenius Medical Care (FME) announces divestments as part of its Portfolio Optimization Program, with a focus on improving leverage ratio and simplifying the company's portfolio. The company has already closed transactions in Argentina and the US, with additional divestments in progress. The divested assets include 127 facilities, more than 4,500 employees, and more than 10,000 dialysis patients, representing a total proforma revenue of around EUR 600 million in 2022. The company expects net proceeds of around EUR 500 million from the divestments, with the remainder to occur in 2024. However, the divestments are estimated to negatively impact 2025 revenue by EUR 1.5 billion but positively impact 2025 margin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Summary
Fresenius Medical Care (FMS) completes change of legal form to Aktiengesellschaft (AG), strengthening corporate governance structure, free float shareholders, and flexibility. The Management Board remains unchanged, while the new Supervisory Board takes office immediately. The business model and strategic plan continue to drive improved operating performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
Rhea-AI Summary
Fresenius Medical Care (FME, FMS) resolves legal dispute with the U.S. government, expecting a net positive impact on operating income of approx. EUR 175 million in Q4 2023. The company raises its earnings outlook, anticipating a 12 to 14 percent growth in operating income in fiscal year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Fresenius Medical Care AG
NYSE:FMS
FMS Rankings
FMS Stock Data
12.31B
198.83M
7.3%
0.19%
Kidney Dialysis Centers
Health Care and Social Assistance
United States of America
Bad Homburg Vor Der Hohe
About FMS
Fresenius Medical Care AG & Co. KGaA is an American German healthcare company which provides kidney dialysis services.